

## Appendix F: TRIPOD checklist

				001
				002
				003
				004
				005
				006
				007
				008
				009
				010
				011
				012
				013
				014
				015
				016
				017
				018
				019
				020
				021
				022
				023
				024
				025
				026
				027
				028
				029
				030
				031
				032
				033
				034
				035
				036
				037
				038
				039
				040
				041
				042
				043
				044
				045
				046

Continued on next page.

047 Table 1 – continued from previous page  
048

049	050	Section/Topic	Item	Checklist Item	Section	
051	052	053	054	055	056	
<hr/>						
057	058	<b>Methods</b>				
<hr/>						
060	061	062	063	064	065	
066	067	068	069	070	071	
072	073	074	075	076	077	
078	079	080	081	082	083	
084	085	086	087	088	089	
090	091	092	Source of data			
<hr/>						
093	094	095	096	097	098	
099	100	101	102	103	104	
105	106	107	108	109	110	
111	112	113	114	115	116	
117	118	119	120	121	122	
123	124	125	126	127	128	
129	130	131	132	133	134	
135	136	137	138	139	140	
141	142	143	144	145	146	
147	148	149	150	151	152	
153	154	155	156	157	158	
159	160	161	162	163	164	
165	166	167	168	169	170	
171	172	173	174	175	176	
177	178	179	180	181	182	
183	184	185	186	187	188	
189	190	191	192	193	194	
195	196	197	198	199	200	
201	202	203	204	205	206	
207	208	209	210	211	212	
213	214	215	216	217	218	
219	220	221	222	223	224	
225	226	227	228	229	230	
231	232	233	234	235	236	
237	238	239	240	241	242	
243	244	245	246	247	248	
249	250	251	252	253	254	
255	256	257	258	259	260	
261	262	263	264	265	266	
267	268	269	270	271	272	
273	274	275	276	277	278	
279	280	281	282	283	284	
285	286	287	288	289	290	
291	292	293	294	295	296	
297	298	299	300	301	302	
303	304	305	306	307	308	
309	310	311	312	313	314	
315	316	317	318	319	320	
321	322	323	324	325	326	
327	328	329	330	331	332	
333	334	335	336	337	338	
339	340	341	342	343	344	
345	346	347	348	349	350	
351	352	353	354	355	356	
357	358	359	360	361	362	
363	364	365	366	367	368	
369	370	371	372	373	374	
375	376	377	378	379	380	
381	382	383	384	385	386	
387	388	389	390	391	392	
393	394	395	396	397	398	
399	400	401	402	403	404	
405	406	407	408	409	410	
411	412	413	414	415	416	
417	418	419	420	421	422	
423	424	425	426	427	428	
429	430	431	432	433	434	
435	436	437	438	439	440	
441	442	443	444	445	446	
447	448	449	450	451	452	
453	454	455	456	457	458	
459	460	461	462	463	464	
465	466	467	468	469	470	
471	472	473	474	475	476	
477	478	479	480	481	482	
483	484	485	486	487	488	
489	490	491	492	493	494	
495	496	497	498	499	500	
501	502	503	504	505	506	
507	508	509	510	511	512	
513	514	515	516	517	518	
519	520	521	522	523	524	
525	526	527	528	529	530	
531	532	533	534	535	536	
537	538	539	540	541	542	
543	544	545	546	547	548	
549	550	551	552	553	554	
555	556	557	558	559	560	
561	562	563	564	565	566	
567	568	569	570	571	572	
573	574	575	576	577	578	
579	580	581	582	583	584	
585	586	587	588	589	590	
591	592	593	594	595	596	
597	598	599	600	601	602	
603	604	605	606	607	608	
609	610	611	612	613	614	
615	616	617	618	619	620	
621	622	623	624	625	626	
627	628	629	630	631	632	
633	634	635	636	637	638	
639	640	641	642	643	644	
645	646	647	648	649	650	
651	652	653	654	655	656	
657	658	659	660	661	662	
663	664	665	666	667	668	
669	670	671	672	673	674	
675	676	677	678	679	680	
681	682	683	684	685	686	
687	688	689	690	691	692	
693	694	695	696	697	698	
699	700	701	702	703	704	
705	706	707	708	709	7010	
7011	7012	7013	7014	7015	7016	
7017	7018	7019	7020	7021	7022	
7023	7024	7025	7026	7027	7028	
7029	7030	7031	7032	7033	7034	
7035	7036	7037	7038	7039	7030	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041	7042	7043	7044	
7045	7046	7047	7048	7049	7040	
7041	7042	7043	7044	7045	7046	
7047	7048	7049	7040	7041	7042	
7043	7044	7045	7046	7047	7048	
7049	7040	7041</				

Table 1 – continued from previous page

Section/Topic	Item	Checklist Item	Section	
	5c	Give details of treatments received, if relevant.	n.a.	093 094
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	2.1	095 096 097 098 099 100 101 102 103 104 105 106
	6b	Report any actions to blind assessment of the outcome to be predicted.	n.a.	107 108 109 110 111 112 113 114 115 116 117 118 119 120
Predictors	7a	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	2.3-2.6	121 122 123 124 125 126 127 128 129
	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.	n.a.	130 131 132 133 134 135 136 137 138
Sample size	8	Explain how the study size was arrived at.	2.1	Continued on next page.

139 Table 1 – continued from previous page  
140

141 <b>Section/Topic</b>	142 <b>Item</b>	143 <b>Checklist Item</b>	144 <b>Section</b>
143 Missing data	9	144 Describe how missing data 145 were handled (e.g., complete- 146 case analysis, single impu- 147 tation, multiple imputation) 148 with details of any imputation 149 method.	150 2.1
153 Statistical analysis methods	10a	154 Describe how predictors were 155 handled in the analyses.	156 2.3-2.6
157	10b	158 Specify type of model, all 159 model-building procedures 160 (including any predictor selec- 161 tion), and method for internal 162 validation.	163 2.4-2.6
165	10c	166 Specify all measures used to 167 assess model performance and, 168 if relevant, to compare multiple 169 models.	170 2.5-2.6
172 Risk groups	11	173 Provide details on how risk 174 groups were created, if done.	175 n.a.
<b>176 Results</b>			
177	Continued on next page.		
178			
179			
180			
181			
182			
183			
184			

Table 1 – continued from previous page

Section/Topic	Item	Checklist Item	Section	
Participants	13a	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	3.1	185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200
	13b	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	3.1	201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222
Model development	14a	Specify the number of participants and outcome events in each analysis.	3.1	223 224 225 226 227 228 229 230
	14b	If done, report the unadjusted association between each candidate predictor and outcome.	n.a.	223 224 225 226 227 228 229 230
		Continued on next page.		

231 Table 1 – continued from previous page  
232

233 <b>Section/Topic</b>	234 <b>Item</b>	235 <b>Checklist Item</b>	236 <b>Section</b>
237 Model specification	238	239 15a Present the full prediction 240 model to allow predictions for 241 individuals (i.e., all regression 242 coefficients, and model inter- 243 cept or baseline survival at a 244 given time point).	245 3.4
245	246	247 15b Explain how to use the prediction model.	n.a.
248 Model performance	249	250 16 Report performance measures (with CIs) for the prediction 251 model.	252 3.4-3.6
<hr/>			
<b>253 Discussion</b>			
<hr/>			
256 Limitations	257	258 18 Discuss any limitations of the study (such as nonrepresenta- 259 tive sample, few events per pre- 260 dictor, missing data).	261 4
262 Interpretation	263	264 19b Give an overall interpretation of the results, consider- 265 ing objectives, limitations, and 266 results from similar studies, 267 and other relevant evidence.	268 4
269	270		
271	272	Continued on next page.	
273	274		
275	276		

Table 1 – continued from previous page

<b>Section/Topic</b>	<b>Item</b>	<b>Checklist Item</b>	<b>Section</b>	
Implications	20	Discuss the potential clinical use of the model and implications for future research.	4	277 278 279 280 281 282 283 284 285
<b>Other information</b>				286 287
Supplementary information	21	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Declarations	288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322
Funding	22	Give the source of funding and the role of the funders for the present study.	Declarations	